Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.

ABSTRACT: Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden and provide unique insights into the evolving molecular landscape of cancers under the selective pressure of immunotherapy. Tracking the landscape of genomic alterations detected in ctDNA may reveal the clonal architecture of the metastatic cascade and thus improve our understanding of the molecular wiring of therapeutic responses. While liquid biopsies may provide a rapid and accurate evaluation of tumor burden dynamics during immunotherapy, the complexity of antitumor immune responses is not fully captured through single-feature ctDNA analyses. This underscores a need for integrative studies modeling the tumor and the immune compartment to understand the kinetics of tumor clearance in association w

SUBMITTER: Sivapalan L 

PROVIDER: S-EPMC9853269 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature